ABSTRACT
Adipocytes are highly differentiated cells and numerous genes are expressed significantly in fat cells, resistin is an adipocytokine highly expressed in murine adipose tissue. Peroxisome proliferator-activated gamma agonists [PPAR] down-regulate resistin gene expression in adipose tissue. The aim of the present work is to clarify the effect of peroxisome proliferator-activated gamma agonist [rosiglitazone] on resistin in obese rats and obese rats with type 2 diabetes. Forty eight white albino male rats of 150-250gm average weight were randomly divided into group 1: Control group [n=8], group 2: [n=8] rats received rosiglitazone, group 3s [n=32] obese rats, this group subdivided into group 3a: Obese rats recieved the drug [n=8]. Group 3b: Obese rats after induction of type 2 diabetes, Group 3c: Obese rats with diabetes and rosiglitazone [n=8]. At the time of scarification blood was collected and samples from central fat and peripheral fat was taken. The following parameters were assessed, serum glucose, triglycerides, cholesterol, insulin, serum resistin and resistin in fats. The results of the present work showed that serum glucose, insulin, triglycerides and cholesterol were significantly higher in [group 3, group 3b] compared to the control while their levels decreased after administration of the drug [Group 3c]. As regard resistin level in serum, central fat and peripheral fat were significantly higher in [group 3 and group 3b] compared to the control however its level significantly decrease after rosiglitazone administration. Also significant correlation were found between serum resistin and serum glucose, serum triglycerides and body mass index in all studied groups. Conclusion resistin seems to play an important role in development of type 2 diabetes particularly on top of obesity and its response to [PPAR] agonist may be used to relive insulin resistance in type 2 diabetes